Hims & Hers Health (NYSE:HIMS) Raised to “Buy” at Wall Street Zen

Hims & Hers Health (NYSE:HIMS) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

HIMS has been the subject of several other reports. Citigroup reissued a “sell” rating and issued a $30.00 price objective (up from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Bank of America increased their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a report on Tuesday, April 29th. UBS Group reissued a “mixed” rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, TD Cowen cut Hims & Hers Health from a “buy” rating to a “hold” rating and cut their price target for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $37.67.

Hims & Hers Health Trading Up 2.6%

HIMS stock opened at $54.89 on Thursday. The company has a market capitalization of $12.29 billion, a P/E ratio of 124.75 and a beta of 1.84. Hims & Hers Health has a twelve month low of $13.47 and a twelve month high of $72.98. The business has a 50 day simple moving average of $37.95 and a 200-day simple moving average of $35.00.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue was up 110.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.05 earnings per share. Research analysts predict that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $48.14, for a total value of $832,966.42. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at approximately $9,319,952.14. This represents a 8.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 3,236 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $27.77, for a total value of $89,863.72. Following the completion of the transaction, the insider now owns 170,285 shares of the company’s stock, valued at $4,728,814.45. The trade was a 1.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold 618,936 shares of company stock worth $25,182,692 over the last 90 days. 13.71% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HIMS. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its position in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the first quarter valued at $30,000. Finally, Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.